Nasopharyngeal carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Evaluation of ERCC1 expression is not appropriate with a biomarker to detect cases who can benefit from PCT in NPC.
|
31169219 |
2019 |
Nasopharyngeal carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The pooled results showed that high/positive expression of ERCC1 predicted poor objective response rate (ORR) [odds ratio (OR) = 2.83; 95% confidence interval (CI) = 2.11-3.80; P <.001], overall survival (OS) [hazard ratio (HR) = 1.77; 95% CI = 1.48-2.12; P <.001], and disease-free survival (DFS) (HR = 1.60; 95% CI = 1.43-1.79; P <.001) in NPC.
|
31124943 |
2019 |
Nasopharyngeal carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
ERCC1 expression might be a useful predictive marker in patients with locoregionally advanced NPC receiving cisplatin-based concurrent chemoradiotherapy.
|
29439312 |
2018 |
Nasopharyngeal carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
ERCC1 expression may be a useful predictive marker in patients with locoregionally advanced NPC, who are receiving cisplatin-based CCRT.
|
29578165 |
2018 |
Nasopharyngeal carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Expression of BRCA1 and ERCC1 as predictive clinical outcome after radiochemotherapy in patients with locoregionally moderate-advanced nasopharyngeal carcinoma.
|
28404895 |
2017 |
Nasopharyngeal carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Combined Ki67 and ERCC1 can better predict nasopharyngeal carcinoma prognosis than individual parameters.
|
29179456 |
2017 |
Nasopharyngeal carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The expression level of ERCC1 in NPC tissues was detected by immunohistochemistry.
|
27721259 |
2016 |
Nasopharyngeal carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The expression of ERCC1 may be a sensitive prognostic indicator of concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma.
|
26125779 |
2015 |
Nasopharyngeal carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The authors hypothesized that the ERCC1 genotype for the SNPs cytosine-to-thymine substitution at codon 118 (C118T) and cytosine-to-adenine substitution at codon 8092 (C8092A) is prognostic in patients with nasopharyngeal carcinoma (NPC) who receive either radiotherapy (RT) or cisplatin plus RT.
|
25946469 |
2015 |
Nasopharyngeal carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The ERCC1 Cys8092Ala polymorphism is an independent predictor of response to radiotherapy for NPC, and the XRCC1 Arg399Glu mutation combined with smoking status seems to predict PFS as well.
|
25025378 |
2014 |
Nasopharyngeal carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The ERCC1 C8092A polymorphism might be a useful predictive marker in metastatic/recurrent NPC patients treated with cisplatin-based chemotherapy.
|
23712330 |
2013 |
Nasopharyngeal carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
High ERCC1 expression predicts poor locoregional control in NPC.
|
20605357 |
2011 |
Nasopharyngeal carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pre-treatment tumor biopsy specimens from 41 patients with locally advanced NPC (stage I: 1, II: 10, III: 9, IV: 21 patients) were analyzed for ERCC1 and TS expression by immunohistochemistry.
|
20153243 |
2010 |
Nasopharyngeal carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Nasopharyngeal carcinoma (NPC) is a platinum-sensitive cancer and excision repair cross-complementing group 1 (ERCC1) polymorphisms have been shown to predict survival in several cancers following platinum therapy.
|
19549713 |
2009 |
Nasopharyngeal carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results suggested that the polymorphism of ERCC1 8092 C > A might be a contributing factor in the development of NPC in Chinese population.
|
18615480 |
2009 |